GUARD DURING ISCHEMIA AGAINST NECROSIS (GUARDIAN)

GUARDIAN试验是一项双盲、安慰剂对照的多国试验，旨在研究NA+/H+交换抑制剂（cariporide）（HOE 642）对存在冠状动脉疾病心肌损伤风险的患者的患者死亡率和心肌梗死的影响。 本研究的主要目的是研究卡立泊利是否可以降低冠状动脉介入手术或冠状动脉旁路移植术期间存在心肌损伤风险的患者的死亡和心肌梗死发生率。此外，还将评估这种新药的安全性和耐受性。

The GUARDIAN Trial is a double-blind, placebo controlled multinational trial to investigate the effects of a NA+/H+ exchange inhibitor (cariporide), (HOE 642) on patient mortality and myocardial infarction in patients who are at risk of myocardial damage due to coronary artery disease. The primary purpose of the study is to investigate whether cariporide can reduce the incidence of death and myocardial infarction in patients who are at risk of myocardial damage during a coronary interventional procedure or coronary artery bypass graft surgery. Additionally, the safety and tolerability of this new drug will be evaluated.